Role of Magnesium suplhate to mother in protecting brain of preterm babies
Not Applicable
- Conditions
- Health Condition 1: null- Preterm infants
- Registration Number
- CTRI/2018/06/014386
- Lead Sponsor
- PGIMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Gestational age less than or equal to 32 weeks
2. Singleton or multiple pregnancy at risk for preterm delivery within the next 24 hours
3.Active preterm labor with cervix 4â??8 cm dilated or preterm premature rupture of membranes or Indicated preterm birth within the next 24 hours
Exclusion Criteria
1.Maternal contraindications to receiving magnesium sulfate like renal failure, cardiac arrhythmia, myasthenia gravis, hypersensitive to drug, heart block, diabetic coma, electrolyte disorder
2.Preeclampsia, eclampsia
3.Fetal distress, abruptio placenta, severe antepartum hemorrhage where urgent delivery is indicated.
4.Precipitate labor
5.Chorioamnionitis
6.Major fetal abnormalities
7.Intrauterine fetal death
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Combined outcome of mortality or abnormal neurodevelopmental outcome at 6 months of corrected age as determined by developmental assessment scale for Indian infants (DASII)Timepoint: after birth to 6 months of corrected age
- Secondary Outcome Measures
Name Time Method 2.Neurodevelopmental outcome as determined by developmental assessment scale for Indian infants (DASII)Timepoint: 6 months;Maternal adverse events following magnesium sulphate infusionTimepoint: till maternal discharge;Neonatal mortalityTimepoint: after birth